---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004612"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2022-03-25T23:59:59+00:00"
generated_at: "2026-06-26T17:12:27.576813+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma appoints Michael L. Derby to Board of Directors

## Summary
- Appointed effective March 24, 2022; term expires at 2022 annual meeting.
- Receives standard non-employee director compensation: $30,000 annual cash plus equity awards.
- Appointment fulfills undertaking from Grace Therapeutics acquisition (Aug 2021) to designate a Grace stockholder representative.
- Derby has over 20 years biopharma experience; founded/co-founded seven companies including TardiMed Sciences.
- Board determined Derby is independent under SEC and Nasdaq rules.

## SEC filing metadata
- accession: 0000950170-22-004612
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2022-03-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017022004612/0000950170-22-004612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017022004612/acst-20220324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004612
- JSON: https://secwatch.observer/filing/0000950170-22-004612.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004612.txt

## Key facts
- Executive change
  Michael L. Derby was appointed as Director at Grace Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 24, 2022, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) appointed Michael L. Derby to the Board as a director, effective as of March 24, 2022, with a term expiring at the 2022 annual meeting of stockholders or until his successor is elected and qualified, or, if earlier, until his death, disability, resignation, disqualification, or removal from the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017022004612/0000950170-22-004612-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.